Table 1.
Clinical characteristics of the patients with breast cancer
| Patient | Case 1 | Case 2 | Case 3 | Case 4 | Case 5 |
|---|---|---|---|---|---|
| Age (years) | 34 | 60 | 51 | 59 | 45 |
| BMI | 23.7 | 19.6 | 25.1 | 17.8 | 30.7 |
| Age at first period (years) | 14 | 15 | 15 | 13 | 14 |
| Age at first birth (years) | 18 | 17 | 17 | 18 | 18 |
| ECOG score [21] | 1 | 3 | 2 | 2 | 3 |
| Preoperative lump size (cm) | 4 × 3 | 5 × 3 | 6 × 4 | 4 × 2 | 10 × 8 |
| TNM Stage | T1N0MX | T4N0M0 | T2N1M0 | T2N0M0 | T2N2MX |
| ER | Negative | Positive (80 %) | Positive (90 %) | Positive (80 %) | Negative |
| PR | Negative | Positive (80 %) | Positive (85 %) | Negative | Negative |
| HER2 | Positive (score: 3+) | Negative | Negative | Negative | Positive (score: 3+) |
| Fish oil dosage (gm/day) | 1.2 | 1.8 | 1.8 | 1.8 | 1.8 |
| No. of days of fish oil supplementation | 130 | 130 | 188a | 136 | 132 |
| No. of capsules per day | Four | Six | Six | Six | Six |
| Chemotherapy regimen | Adriamycin (72mg/100ml/10min), 5-fluorouracil (725mg/100ml/10min), cyclophosphamide (725mg/500ml/10min) | Doxorubicin (60mg/100ml/10min), 5-fluorouracil (685mg/100ml/10min), cyclophosphamide (685mg/500ml/60min) | Doxorubicin (70mg/100ml/10min), 5-fluorouracil (700mg/100ml/10min), cyclophosphamide (700mg/500ml/60min) | Paclitaxel (220mg/500ml/180min) | Doxorubicin (90mg/100ml/10min), 5-fluorouracil (900mg/100ml/10min), cyclophosphamide (900mg/500ml/60min) |
BMI body mass index, ECOG Eastern Cooperative Oncology Group, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor
aThe increase in the number of days was due to patient’s delay in undertaking chemotherapy on time because of her financial restrictions